The End of Alzheimer’s, by Dale Bredesen, MD, is finally out. I’ve been waiting forever.

Clinical studies using Bredesen’s ReCODE protocol are showing breakthrough results on patients with mild to moderate Alzheimer’s Disease as well as pre-Alzheimer’s. Over 200 patient success stories exist now, some of them breathtaking. In each case the disease was documented before treatment.

Bredesen’s basic science research on Alzheimer’s Disease has been published in peer-reviewed journals for 28 years, yet strangely his successful clinical protocol papers have received the cold shoulder from the medical establishment.

Is this because Bredesen is going after the causes while mainstream medicine is interested only in masking the symptoms? No. It may look that way, but the truth is much more interesting.

It boils down to a rigid devotion to traditional experimental design which insists that each component of any therapy must be studied separately. Yes, rarely they’ll make exceptions and study two medications simultaneously in the treatment of certain diseases, but the moon has to be just right for such madness.

Historically this monotherapy approach has worked fairly well for certain diseases that have a single cause, but it creates a roadblock to research on complex diseases such as Alzheimer’s.

Though the clinical evidence against monotherapy for Alzheimer’s is a billion dollar wasteland, medical authorities cling to the failed dogma like the scientific fundamentalists who have gone before them throughout the history of medicine and science in general, holding back major progress for a sacred flawed belief that must hold sway.

In the case of Alzheimer’s Disease, the belief is simple: if you don’t isolate one thing at a time you’ll never know exactly what that one thing does in isolation. Brilliant deduction. The assumption, though, is that knowing what each thing does in isolation should always be the goal of science.

Reductionism.

But as Emerson said, “Foolish consistency is the hobgoblin of small minds.”

In medical science, understanding a system as a functioning whole in both disease and in health is more central than reductionism to the overall goal, which is saving patients’ lives.

Bredesen’s protocol is doing exactly that, as documented in peer-reviewed journals.

Disease complexity is why monotherapy experimental design has made no progress against Alzheimer’s Disease. This is a disease with at least 36 to 50 different “things” that can go wrong together in various combinations that cause the mind to fail. The number and mix of partial causes differs from one patient to the next, but three broad categories have arisen: Inflammatory, atrophic and toxic.

All three produce the same pathognomonic plaques and tangles under light microscopy, so pathologists consider Alzheimer’s a single disease. It’s not.

Testing each of the 36 to 50 therapeutic elements in isolation, if it were possible, would take many decades and result in negative or equivocal outcomes because:

1. Each component of Bredesen’s protocol reverses a small fraction of the 36 to 50 disease-promoting processes, and those processes are not uniformly distributed in the Alzheimer’s population. So anything tested in isolation will not likely have enough effect to be statistically significant. Vitamin E is an exception, but in general, the total therapy (individualized to each patient through multiple tests) is needed to reverse Alzheimer’s Disease.

2. The synergistic effects of therapeutic components are eliminated by monotherapy-biased experimental design.

To ignore Bredesen’s work as the orthodox mainstream still wants to do is the moral equivalent of violent abuse to Alzheimer’s patients and their families.

If you know anyone with Alzheimer’s disease or early cognitive decline, do them the biggest favor of their lives. Read Dale Bredesen’s breakthrough book for yourself and share your knowledge with them. Then perhaps they won’t be fooled by the supercilious, sophisticated-sounding monotherapy devotees who are determined to wait for a prescription pill from a drug company and watch their patients die.

Wow, that was harsh. But true.

Anyway, here’s a recent (Oct. 2018) video interview of Dale Bredesen done by Rhonda Patrick, Ph.D., a hugely talented and well-informed research scientists, discussing the groundbreaking, unprecedented results of the ReCODE protocol. Enjoy!

Here’s a somewhat less recent interview of Dr. Bredesen done by Steven Gundry, MD, a world-renowned heart surgeon.

“It’s fun to have fun, but you’ve got to know how.” — Dr. Seuss.

Morrill Talmage Moorehead, MD
Retired pathologist, speculative fiction writer and content editor.

(I have no conflict of interest and no personal acquaintance with Dr. Bredesen.)

)

Written by

Former pathologist, current writer. Here's my blog: www.storiform.com.

Welcome to a place where words matter. On Medium, smart voices and original ideas take center stage - with no ads in sight. Watch
Follow all the topics you care about, and we’ll deliver the best stories for you to your homepage and inbox. Explore
Get unlimited access to the best stories on Medium — and support writers while you’re at it. Just $5/month. Upgrade